Belite Bio: Bioptima proposes $679K share sale

The 4,000 ADSs are identified as acquired through RSU vesting on October 8, 2025.

Rhea-AI Filing Summary

Belite Bio, Inc. (BLTE) is the issuer for a proposed sale of 4,000 American Depositary Shares, each representing one ordinary share, with an aggregate market value of $679,280. The remarks name Bioptima AG as the seller and describe Hendrik Peter Scholl as a director; the relationship field identifies Scholl as an officer. The shares are to be sold today or within three months from October 1, 2026, and J.P. Morgan Securities LLC is named as broker.

Key Figures

Proposed sale: 4,000 American Depositary Shares Aggregate market value: $679,280 ADS representation: 1 ordinary share per American Depositary Share +1 more

4 metrics

Proposed sale 4,000 American Depositary Shares Proposed sale of Belite Bio securities

Aggregate market value $679,280 Proposed sale

ADS representation 1 ordinary share per American Depositary Share Each ADS represents one ordinary share

Acquired through RSU vesting 4,000 American Depositary Shares Acquired October 8, 2025

Key Terms

American Depositary Shares, RSU Vesting, Rule 144, aggregate market value

4 terms

American Depositary Shares financial

"American Depositary Shares, each representing one ordinary share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

RSU Vesting financial

"RSU Vesting"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BLTE ADSs are proposed for sale?

The proposed sale covers 4,000 ADSs with an aggregate market value of $679,280. Bioptima AG is identified as the seller, and the remarks say the shares will be sold today or within three months from October 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 06:04 PM Accepted by SEC EDGAR 10/01/2026 - 06:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002113223
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Belite Bio, Inc.
SEC File Number	001-41359
Address of Issuer	12750 High Bluff Drive Suite 475 San Diego CALIFORNIA 92130
Phone	858-246-6240
Name of Person for Whose Account the Securities are To Be Sold	Hendrik Peter Scholl
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares, each representing one ordinary share	J.P. Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	4000	679280	39339960	10/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares, each representing one ordinary share	10/08/2025	RSU Vesting	Issuer			4000	10/08/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The shares covered by this filing will be sold by Bioptima AG, Hendrik Peter Scholl as Director. The shares will be sold today or within three months from the date of this filing.
Date of Notice	10/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Hendrik Peter Scholl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)